Xiuwei H. Yang

Dr. Xiuwei H. Yang

Department of Pharmacology and Nutritional Sciences, University of Kentucky, 800 Rose St., MS-366/MS-305, Lexington, KY 40536-0298, USA
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
XYXiuwei H. Yang
Xiuwei H. Yang
LFLudmila M. Flores
Ludmila M. Flores
QLQinglin Li
Qinglin Li
PZPengcheng Zhou
Pengcheng Zhou
FXFenghui Xu
Fenghui Xu
MHMartin Hemler
Martin Hemler
Resistance to anti-ErbB2 agents is a significant problem in the treatment of human ErbB2+ breast cancers. We show here that adhesion of human ErbB2+ breast cancer cells to basement membrane laminin-5 provides substantial resistance to trastuzumab and lapatinib, agents that respectively target the extracellular and kinase domains of ErbB2. Knockdown of laminin-binding integrins (α6β4, α3β1) or associated tetraspanin protein CD151 reversed laminin-5 resistance and sensitized ErbB2+ cells to trastuzumab and lapatinib. CD151 knockdown, together with trastuzumab treatment, inhibited ErbB2 activation and downstream signaling through Akt, Erk1/2, and focal adhesion kinase (FAK). Hence, ErbB2 function in mammary tumor cells is promoted by integrin-mediated adhesion to laminin-5, with strong support by CD151, leading to signaling through FAK. Consequently, removal or inhibition of any of these components (laminin-5, integrin, CD151, FAK) markedly sensitizes cells to anti-ErbB2 agents. These new insights should be useful when devising strategies for overcoming drug resistance in ErbB2+ cancers. Cancer Res; 70(6); 2256–63

13 August 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
PZPengcheng Zhou
Pengcheng Zhou
SESonia Erfani
Sonia Erfani
ZLZeyi Liu
Zeyi Liu
CJChanghe Jia
Changhe Jia
YCYecang Chen
Yecang Chen
XYXiuwei H. Yang
Xiuwei H. Yang
CD151-31 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion

30 January 2017 in Oncogenesis
Verified
Journal Article
Open access
PDF file
BXB Xu
B Xu
JLJ Lefringhouse
J Lefringhouse
ZLZ Liu
Z Liu
DWD West
D West
LBL A Baldwin
L A Baldwin
XYXiuwei H. Yang
Xiuwei H. Yang
Integrins, a family of heterodimeric receptors for extracellular matrix, are promising therapeutic targets for ovarian cancer, particularly high-grade serous-type (HGSOC), as they drive tumor cell attachment, migration, proliferation and survival by activating focal adhesion kinase (FAK)-dependent signaling. Owing to the potential off-target effects of FAK inhibitors, disruption of the integrin signaling axis remains to be a challenge. Here, we tackled this barrier by screening for inhibitors being functionally cooperative with small-molecule VS-6063, a phase II FAK inhibitor. From this screening, JQ1, a potent inhibitor of Myc oncogenic network, emerged as the most robust collaborator. Treatment with a combination of VS-6063 and JQ1 synergistically caused an arrest of tumor cells at the G2/M phase and a decrease in the XIAP-linked cell survival. Our subsequent mechanistic analyses indicate that this functional cooperation was strongly associated with the concomitant disruption of activation or expression of FAK and c-Myc as well as their downstream signaling through the PI3K/Akt pathway. In line with these observations, we detected a strong co-amplification or upregulation at genomic or protein level for FAK and c-Myc in a large portion of primary tumors in the TCGA or a local HGSOC patient cohort. Taken together, our results suggest that the integrin–FAK signaling axis and c-Myc synergistically drive cell proliferation, survival and oncogenic potential in HGSOC. As such, our study provides key genetic, functional and signaling bases for the small-molecule-based co-targeting of these two distinct oncogenic drivers as a new line of targeted therapy against human ovarian cancer.

1 January 2012 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
XYXiuwei H. Yang
Xiuwei H. Yang
RMRossen Mirchev
Rossen Mirchev
XDXinyu Deng
Xinyu Deng
PYPatrick Yacono
Patrick Yacono
HYHelen L. Yang
Helen L. Yang
MHMartin Hemler
Martin Hemler
Laminin-binding integrins (α3β1, α6β1, α6β4, α7β1) are almost always expressed together with tetraspanin CD151. In every co-expressing cell analyzed to date, CD151 makes a fundamental contribution towards integrin-dependent motility, invasion, morphology, adhesion and/or signaling. However, there has been minimal mechanistic insight into how CD151 affects integrin functions. In MDA-MB-231 mammary cells, tetraspanin CD151 knockdown impairs α6 integrin clustering and functions without decreasing α6 expression or activation. Furthermore, CD151 knockdown minimally affects α6 diffusion magnitude, as measured using single particle tracking. Instead, CD151 knockdown has a novel and unexpected dysregulating effect on α6 integrin diffusion mode. Control cell α6 shows mostly random/confined diffusion (RCD) and some directed motion (DMO). In sharp contrast, CD151 knockdown cell α6 shows mostly DMO. Control α6 diffusion mode is sensitive to actin disruption, talin knockdown, and phorbol ester stimulation. In contrast, CD151 knockdown cell α6 is sensitive to actin disruption but desensitized to talin knockdown or phorbol ester stimulation, indicating dysregulation. Both phorbol ester and EGF stimulate cell spreading and promote α6 RCD in control cells. In contrast, CD151-ablated cells retain EGF effects but lose phorbol ester-stimulated spreading and α6 RCD. For α6 integrins, physical association with CD151 promotes α6 RCD, in support of α6-mediated cable formation and adhesion. By comparison, for integrins not associated with CD151 (e.g. αv integrins), CD151 affects neither diffusion mode, nor αv function. Hence, CD151 support of α6 RCD is specific and functionally relevant, and likely underlies diverse CD151 functions in skin, kidney, and cancer cells.

22 October 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
LBLauren A. Baldwin
Lauren A. Baldwin
JHJohn T. Hoff
John T. Hoff
JLJason Lefringhouse
Jason Lefringhouse
MZMichael Zhang
Michael Zhang
CJChanghe Jia
Changhe Jia
XYXiuwei H. Yang
Xiuwei H. Yang
Human ovarian cancer is diagnosed in the late, metastatic stages but the underlying mechanisms remain poorly understood. We report a surprising functional link between CD151-α3β1 integrin complexes and the malignancy of serous-type ovarian cancer. Analyses of clinical specimens indicate that CD151 expression is significantly reduced or diminished in 90% of metastatic lesions, while it remains detectable in 58% of primary tumors. These observations suggest a putative tumor-suppressing role of CD151 in ovarian cancer. Indeed, our analyses show that knocking down CD151 or α3 integrin enhances tumor cell proliferation, growth and ascites production in nude mice. These changes are accompanied by impaired cell-cell contacts and aberrant expression of E-cadherin, Mucin 5AC and fibronectin, largely reminiscent of an epithelial to mesenchymal transition (EMT)-like change. Importantly, Slug, a master regulator of EMT, is markedly elevated. Knocking down Slug partially restores CD151-α3β1 integrin complex-dependent suppression of cell proliferation. Moreover, disruption of these adhesion protein complexes is accompanied by a concomitant activation of canonical Wnt signaling, including elevated levels of β-catenin and Axin-2 as well as resistance to the inhibition in β-catenin-dependent transcriptional complexes. Together, our study demonstrates that CD151-α3β1 integrin complexes regulate ovarian tumor growth by repressing Slug-mediated EMT and Wnt signaling.

2 October 2020 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
YZYang Zhang
Yang Zhang
BXBingwei Xu
Bingwei Xu
JSJunfeng Shi
Junfeng Shi
JLJieming Li
Jieming Li
XLXinlan Lu
Xinlan Lu
XYXiuwei H. Yang
Xiuwei H. Yang
Purpose: Stemming from a myriad of genetic and epigenetic alterations, triple-negative breast cancer (TNBC) is tied to poor clinical outcomes and aspires for individualized therapies. Here we investigated the therapeutic potential of co-inhibiting integrin-dependent signaling pathway and BRD4, a transcriptional and epigenetic mediator, for TNBC. Methods: Two independent patient cohorts were subjected to bioinformatic and IHC examination for clinical association of candidate cancer drivers. The efficacy and biological bases for co-targeting these drivers were interrogated using cancer cell lines, a protein kinase array, chemical inhibitors, RNAi/CRISPR/Cas9 approaches, and a 4 T1-Balb/c xenograft model. Results: We found that amplification of the chromosome 8q24 region occurred in nearly 20% of TNBC tumors, and that it coincided with co-upregulation or amplification of c-Myc and FAK, a key effector of integrin-dependent signaling. This co-upregulation at the mRNA or protein level correlated with a poor patient survival (p < 0.0109 or p < 0.0402, respectively). Furthermore, we found that 14 TNBC cell lines exhibited high vulnerabilities to the combination of JQ1 and VS-6063, potent pharmacological antagonists of the BRD4/c-Myc and integrin/FAK-dependent pathways, respectively. We also observed a cooperative inhibitory effect of JQ1 and VS-6063 on tumor growth and infiltration of Ly6G+ myeloid-derived suppressor cells in vivo. Finally, we found that JQ1 and VS-6063 cooperatively induced apoptotic cell death by altering XIAP, Bcl2/Bcl-xl and Bim levels, impairing c-Src/p130Cas-, PI3K/Akt- and RelA-associated signaling, and were linked to EMT-inducing transcription factor Snail- and Slug-dependent regulation. Conclusion: Based on our results, we conclude that the BRD4/c-Myc- and integrin/FAK-dependent pathways act in concert to promote breast cancer cell survival and poor clinical outcomes. As such, they represent promising targets for a synthetic lethal-type of therapy against TNBC.